Corluxin: Withdrawal of the marketing authorisation application


On 23 March 2015, FGK Representative Service GmbH officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Corluxin, intended for the treatment of Cushing's syndrome.

  • List item

    Questions and answers on the withdrawal of the marketing authorisation application for Corluxin (mifepristone) (PDF/80.23 KB)

    First published: 22/05/2015
    Last updated: 22/05/2015

  • Key facts

    Product number
    Active substance
    • mifepristone
    Date of withdrawal
    Company making the application
    FGK Representative Service GmbH
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating